Lead Product(s): OTO-6XX
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTO-6XX
Highest Development Status: Preclinical Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 03, 2020
Otonomy, entered exclusive license agreement with KYORIN Pharmaceutical that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.